Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2014

Open Access 01-12-2014 | Research article

Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden

Authors: Barbara Eržen, Mira Šilar, Mišo Šabovič

Published in: BMC Cardiovascular Disorders | Issue 1/2014

Login to get access

Abstract

Background

The role of vascular endothelial growth factor (VEGF) in patients in the stable phase after myocardial infarction (MI) has not yet been explored. Therefore, we compared the values of VEGF in post-MI patients with those obtained in healthy controls. Furthermore, we investigated whether the values of VEGF correlate to either inflammation markers or the atherosclerotic burden.

Methods

41 male patients (on average 44 years old) in the stable phase after MI (on average 20.5 months after MI) were recruited, while 25 healthy age-matched males served as controls. Plasma levels of VEGF and several markers of inflammation were measured by standard procedures. The atherosclerotic burden was determined by the angiographic severity of coronary atherosclerosis, endothelial dysfunction (measured by ultrasound measurement of the flow mediated dilation of the brachial artery), the intima-media thickness of the common carotid artery and the ankle-brachial pressure index.

Results

VEGF values were significantly elevated in post-MI patients compared to the controls (53.8 ± 42.7 pg/ml vs. 36.3 ± 8.9 pg/ml, p = 0.014). The elevated VEGF values significantly correlated to the (increased) values of the inflammatory molecules interleukin 6 and 8 (r = 0.37, p = 0.017; and r = 0.45, p = 0.003; respectively). In contrast, no correlation was found between VEGF and the parameters of the atherosclerotic burden, although FMD and IMT were significantly impaired in patients.

Conclusions

We found that plasma levels of VEGF are increased in the stable phase after MI and correlate with inflammation cytokines, but not with the atherosclerotic burden. Thus, this suggests that increased levels of VEGF are a part of ongoing inflammatory activity. Since VEGF in these patients stimulates neovascularization of inflamed plaques and induces their destabilization, the VEGF level can have an important negative prognostic value. Clearly, further studies are needed to clarify the role of VEGF as a prognostic marker.
Appendix
Available only for authorised users
Literature
1.
go back to reference Taniguchi T, Sawada T: Significance of measuring plasma vascular endothelial growth factor in patients with acute myocardial infarction. Circ J. 2012, 76 (6): 1331-1332. 10.1253/circj.CJ-12-0473.CrossRefPubMed Taniguchi T, Sawada T: Significance of measuring plasma vascular endothelial growth factor in patients with acute myocardial infarction. Circ J. 2012, 76 (6): 1331-1332. 10.1253/circj.CJ-12-0473.CrossRefPubMed
2.
go back to reference Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669.CrossRefPubMed Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669.CrossRefPubMed
3.
go back to reference Shinohara K, Shinohara T, Mochizuki N, Mochizuki Y, Sawa H, Kohya T, Fujita M, Fujioka Y, Kitabatake A, Nagashima K: Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels. 1996, 11 (3): 113-122. 10.1007/BF01745169.CrossRefPubMed Shinohara K, Shinohara T, Mochizuki N, Mochizuki Y, Sawa H, Kohya T, Fujita M, Fujioka Y, Kitabatake A, Nagashima K: Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels. 1996, 11 (3): 113-122. 10.1007/BF01745169.CrossRefPubMed
4.
go back to reference Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001, 7: 425-429. 10.1038/86490.CrossRefPubMed Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001, 7: 425-429. 10.1038/86490.CrossRefPubMed
5.
go back to reference Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels. 2000, 15 (3): 105-111. 10.1007/PL00007263.CrossRefPubMed Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels. 2000, 15 (3): 105-111. 10.1007/PL00007263.CrossRefPubMed
6.
go back to reference Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, Mitsuhashi H, Ishii H, Kondo T, Murohara T: Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome: results from the Nagoya Acute Myocardial Infarction Study. Circ J. 2012, 76 (6): 1509-1516. 10.1253/circj.CJ-11-1127.CrossRefPubMed Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, Mitsuhashi H, Ishii H, Kondo T, Murohara T: Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome: results from the Nagoya Acute Myocardial Infarction Study. Circ J. 2012, 76 (6): 1509-1516. 10.1253/circj.CJ-11-1127.CrossRefPubMed
7.
go back to reference Ye L, Zhang W, Su LP, Haider HK, Poh KK, Galupo MJ, Songco G, Ge RW, Tan HC, Sim EK: Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials. 2011, 32 (9): 2424-2431. 10.1016/j.biomaterials.2010.12.008.CrossRefPubMed Ye L, Zhang W, Su LP, Haider HK, Poh KK, Galupo MJ, Songco G, Ge RW, Tan HC, Sim EK: Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials. 2011, 32 (9): 2424-2431. 10.1016/j.biomaterials.2010.12.008.CrossRefPubMed
8.
go back to reference Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001, 103 (23): 2776-2779. 10.1161/hc2301.092122.CrossRefPubMed Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001, 103 (23): 2776-2779. 10.1161/hc2301.092122.CrossRefPubMed
9.
go back to reference Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000, 93 (3): 168-174. 10.1159/000007022.CrossRefPubMed Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N: Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000, 93 (3): 168-174. 10.1159/000007022.CrossRefPubMed
10.
go back to reference Kranz A, Rau C, Kochs M, Waltenberger J: Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol. 2000, 32 (1): 65-72. 10.1006/jmcc.1999.1062.CrossRefPubMed Kranz A, Rau C, Kochs M, Waltenberger J: Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol. 2000, 32 (1): 65-72. 10.1006/jmcc.1999.1062.CrossRefPubMed
11.
go back to reference Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003, 107 (4): 524-530. 10.1161/01.CIR.0000048183.37648.1A.CrossRefPubMed Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003, 107 (4): 524-530. 10.1161/01.CIR.0000048183.37648.1A.CrossRefPubMed
12.
go back to reference Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004, 56 (4): 549-580. 10.1124/pr.56.4.3.CrossRefPubMed Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004, 56 (4): 549-580. 10.1124/pr.56.4.3.CrossRefPubMed
13.
go back to reference Gruchala M, Roy H, Bhardwaj S, Yla-Herttuala S: Gene therapy for cardiovascular diseases. Curr Pharm Des. 2004, 10: 407-423. 10.2174/1381612043453379.CrossRefPubMed Gruchala M, Roy H, Bhardwaj S, Yla-Herttuala S: Gene therapy for cardiovascular diseases. Curr Pharm Des. 2004, 10: 407-423. 10.2174/1381612043453379.CrossRefPubMed
14.
go back to reference Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992, 359 (6398): 843-845. 10.1038/359843a0.CrossRefPubMed Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992, 359 (6398): 843-845. 10.1038/359843a0.CrossRefPubMed
15.
go back to reference Seko Y, Imai Y, Suzuki S, Kamijukkoku S, Hayasaki K, Sakomura Y, Tobe K, Kadowaki T, Maekawa H, Takahashi N, Yazaki Y: Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci. 1997, 92 (5): 453-454.CrossRefPubMed Seko Y, Imai Y, Suzuki S, Kamijukkoku S, Hayasaki K, Sakomura Y, Tobe K, Kadowaki T, Maekawa H, Takahashi N, Yazaki Y: Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci. 1997, 92 (5): 453-454.CrossRefPubMed
16.
go back to reference Wojakowski W, Maslankiewicz K, Ochala A, Wyderka R, Zuk-Popiolek I, Flak Z, Mroz I, Tendera M: The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. Int J Mol Med. 2004, 14 (2): 317-322.PubMed Wojakowski W, Maslankiewicz K, Ochala A, Wyderka R, Zuk-Popiolek I, Flak Z, Mroz I, Tendera M: The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. Int J Mol Med. 2004, 14 (2): 317-322.PubMed
17.
go back to reference Kawamoto A, Kawata H, Akai Y, Katsuyama Y, Takase E, Sasaki Y, Tsujimura S, Sakaguchi Y, Iwano M, Fujimoto S, Hashimoto T, Dohi K: Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol. 1998, 67 (1): 47-54. 10.1016/S0167-5273(98)00251-4.CrossRefPubMed Kawamoto A, Kawata H, Akai Y, Katsuyama Y, Takase E, Sasaki Y, Tsujimura S, Sakaguchi Y, Iwano M, Fujimoto S, Hashimoto T, Dohi K: Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol. 1998, 67 (1): 47-54. 10.1016/S0167-5273(98)00251-4.CrossRefPubMed
18.
go back to reference Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GYH: Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003, 89 (12): 1411-1415. 10.1136/heart.89.12.1411.CrossRefPubMedPubMedCentral Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GYH: Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003, 89 (12): 1411-1415. 10.1136/heart.89.12.1411.CrossRefPubMedPubMedCentral
19.
go back to reference Alber HF, Frick M, Dulak J, Do¨rler J, Zwick R-H, Dichtl W, Pachinger O, Weidinger F: Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart. 2005, 91: 365-366. 10.1136/hrt.2003.021311.CrossRefPubMedPubMedCentral Alber HF, Frick M, Dulak J, Do¨rler J, Zwick R-H, Dichtl W, Pachinger O, Weidinger F: Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart. 2005, 91: 365-366. 10.1136/hrt.2003.021311.CrossRefPubMedPubMedCentral
20.
go back to reference Alioglu E, Turk U, Cam S, Abbasaliyev A, Tengiz I, Ercan E: Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness. Can J Cardiol. 2009, 25 (1): e1-e5. 10.1016/S0828-282X(09)70022-4.CrossRefPubMedPubMedCentral Alioglu E, Turk U, Cam S, Abbasaliyev A, Tengiz I, Ercan E: Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness. Can J Cardiol. 2009, 25 (1): e1-e5. 10.1016/S0828-282X(09)70022-4.CrossRefPubMedPubMedCentral
21.
go back to reference Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem. 1998, 273: 30336-30343. 10.1074/jbc.273.46.30336.CrossRefPubMed Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem. 1998, 273: 30336-30343. 10.1074/jbc.273.46.30336.CrossRefPubMed
22.
go back to reference Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S: Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation. 2009, 120 (11 Suppl): S247-S254.CrossRefPubMed Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S: Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation. 2009, 120 (11 Suppl): S247-S254.CrossRefPubMed
Metadata
Title
Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden
Authors
Barbara Eržen
Mira Šilar
Mišo Šabovič
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2014
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-14-166

Other articles of this Issue 1/2014

BMC Cardiovascular Disorders 1/2014 Go to the issue